News

Genmab gained the payment from GlaxoSmithKline which was triggered by the NDA submission of Arzerra. The application seeks approval for the treatment of patients with chronic lymphocytic leukemia

Fycompa (perampanel) is an adjunctive treatment of partial-onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older. Perampanel is a highly

The study is designed to evaluate how MIV-711 affects biomarkers known to be relevant for measuring bone and cartilage turnover and the therapeutic dose levels to be used

The pharmaceutical companies, which have been engaged in the production of these drugs, were issued notices and have been directed to rectify the manufacturing processes, the pharmabiz reported.

As per the agreement, Takeda Brazil will take over Multilab for BRL500m upfront and up to BRL40m in additional future milestone payments to the owners of Multilab. The

The Phase 1 dose-escalating clinical trial in healthy volunteers is designed to assess whether the aqueous formulation of SMT C1100 can provide the consistent levels of drug in

As per the agreement, Ranbaxy will pay royalties on net sales of Absorica to Cipher. Ranbaxy Americas senior vice president and regional director Venkat Krishnan said, "Absorica is

NoPHEDRA contains green tea, caffeine, synephrine citrus aurantium L-Tyrosine, forskolin, flavanex-ER or 5-hydroxytryptophan to help burn fat fast. The new supplement controls one’s food intake and helps boost

SAR236553/REGN727 is a fully human monoclonal antibody that acts by inhibiting PCSK9, a determinant of circulating low-density-lipoprotein cholesterol (LDL-C) levels in the blood, thereby increasing the number of